ValueinValuein

RLYBRallybio Corp

Health Care

Revenues revised up 6.0% for FY 2024

Revenues·FY 2024

Notable restatement
$636K 6.0%

was$600K

Revised up. Any P/S built on the original was 5.7% too high.

No amendment filed
As reported · Mar 13, 2025Restated · Aug 26, 2026us-gaap:Revenues
Verify against SEC filingsShow
As reported$600K
Accepted 2025-03-130001739410-25-000040
Restated$636K
Accepted 2026-08-260001193125-26-368568

TotalRevenue · reported 4 times · point-in-time, survivorship-free. Every figure traces to its filing above.

Track this the moment it happens

Get a signal the next time RLYB — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.